{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:53:10Z","timestamp":1780419190449,"version":"3.54.1"},"reference-count":55,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","elsevier.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.acuroe.2024.04.005","type":"journal-article","created":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T16:32:47Z","timestamp":1712075567000},"page":"262-272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Multidisciplinary consensus document on the current treatment of bacille Calmette-Gu\u00e9rin-unresponsive non-muscle invasive bladder tumor"],"prefix":"10.1016","volume":"48","author":[{"given":"F.","family":"Guerrero-Ramos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"\u00c1lvarez-Maestro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1.","family":"Pinto Mar\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"Dom\u00ednguez Escrig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d3.","family":"Rodr\u00edguez Faba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.acuroe.2024.04.005_bib0005","article-title":"Intravesical Bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer","volume":"1","author":"Schmidt","year":"2020","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.acuroe.2024.04.005_bib0010","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol."},{"key":"10.1016\/j.acuroe.2024.04.005_bib0015","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol."},{"key":"10.1016\/j.acuroe.2024.04.005_bib0020","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3233\/BLC-150039","article-title":"Bacillus Calmette-Guerin (BCG) treatment failures with non-muscle invasive bladder cancer: a data-driven definition for BCG unresponsive disease","volume":"2","author":"Steinberg","year":"2016","journal-title":"Bladder Cancer."},{"key":"10.1016\/j.acuroe.2024.04.005_bib0025","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology Guidelines on non-muscle-invasive bladder cancer (Ta, T1, and Carcinoma in Situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol."},{"key":"10.1016\/j.acuroe.2024.04.005_bib0030","article-title":"Utilization and outcomes of radical cystectomy for high-grade non-muscle-invasive bladder cancer in elderly patients","author":"Parker","year":"2017","journal-title":"Clin Genitourin Cancer."},{"key":"10.1016\/j.acuroe.2024.04.005_bib0035","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-043266","article-title":"Short-term morbidity and mortality following radical cystectomy: a systematic review","volume":"11","author":"Maibom","year":"2021","journal-title":"BMJ Open."},{"key":"10.1016\/j.acuroe.2024.04.005_bib0040","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.eururo.2021.12.005","article-title":"International Bladder Cancer Group Consensus Statement on clinical trial design for patients with Bacillus Calmette-Guerin-exposed high-risk non-muscle-invasive bladder cancer","volume":"82","author":"Roumiguie","year":"2022","journal-title":"Eur Urol."},{"key":"10.1016\/j.acuroe.2024.04.005_bib0045","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.urology.2007.09.050","article-title":"Impact of previous bacille Calmette-Guerin failure pattern on subsequent response to bacille Calmette-Guerin plus interferon intravesical therapy","volume":"71","author":"Gallagher","year":"2008","journal-title":"Urology."},{"key":"10.1016\/j.acuroe.2024.04.005_bib0050","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.acuroe.2024.04.005_bib0055","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol."},{"key":"10.1016\/j.acuroe.2024.04.005_bib0060","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.eururo.2020.02.012","article-title":"Systematic review of the therapeutic efficacy of bladder-preserving treatments for non-muscle-invasive bladder cancer following Intravesical Bacillus Calmette-Guerin","volume":"78","author":"Li","year":"2020","journal-title":"Eur Urol."},{"key":"10.1016\/j.acuroe.2024.04.005_bib0065","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/978-3-642-81565-2_2","article-title":"Preclinical rationale and phase I clinical trial of the adriamycin analog, AD 32","volume":"76","author":"Blum","year":"1981","journal-title":"Recent Results Cancer Res."},{"key":"10.1016\/j.acuroe.2024.04.005_bib0070","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0090-4295(96)00621-8","article-title":"Initial report on intravesical administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder","volume":"49","author":"Greenberg","year":"1997","journal-title":"Urology."},{"key":"10.1016\/j.acuroe.2024.04.005_bib0075","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.urolonc.2008.05.004","article-title":"Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): a trial of the Eastern Cooperative Oncology Group","volume":"27","author":"Ignatoff","year":"2009","journal-title":"Urol Oncol."},{"key":"10.1016\/j.acuroe.2024.04.005_bib0080","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","article-title":"Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group","volume":"163","author":"Steinberg","year":"2000","journal-title":"J Urol."},{"key":"10.1016\/j.acuroe.2024.04.005_bib0085","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.urolonc.2012.04.010","article-title":"Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guerin","volume":"31","author":"Dinney","year":"2013","journal-title":"Urol Oncol."},{"key":"10.1016\/j.acuroe.2024.04.005_bib0090","doi-asserted-by":"crossref","first-page":"35.e21-30","DOI":"10.1016\/j.urolonc.2013.02.010","article-title":"Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer","volume":"32","author":"Lamm","year":"2014","journal-title":"Urol Oncol."},{"key":"10.1016\/j.acuroe.2024.04.005_bib0095","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.ymthe.2004.05.027","article-title":"Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein","volume":"10","author":"Benedict","year":"2004","journal-title":"Mol Ther."},{"key":"10.1016\/j.acuroe.2024.04.005_bib0100","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.urology.2005.02.015","article-title":"Sustained intravesical interferon protein exposure is achieved using an adenoviral-mediated gene delivery system: a study in rats evaluating dosing regimens","volume":"66","author":"Connor","year":"2005","journal-title":"Urology."},{"key":"10.1016\/j.acuroe.2024.04.005_bib0105","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/sj.cgt.7700865","article-title":"Efficacy of a single intravesical treatment with Ad-IFN\/Syn 3 is dependent on dose and urine IFN concentration obtained: implications for clinical investigation","volume":"13","author":"Tao","year":"2006","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.acuroe.2024.04.005_bib0110","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.acuroe.2024.04.005_bib0115","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/JU.0000000000000688","article-title":"Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer","volume":"203","author":"Steinberg","year":"2020","journal-title":"J Urol."},{"key":"10.1016\/j.acuroe.2024.04.005_bib0120","doi-asserted-by":"crossref","first-page":"148.e1-7","DOI":"10.1016\/j.urolonc.2022.10.030","article-title":"Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer","volume":"41","author":"Chevuru","year":"2023","journal-title":"Urol Oncol."},{"key":"10.1016\/j.acuroe.2024.04.005_bib0125","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00345-022-03928-1","article-title":"Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial","volume":"40","author":"Guerrero-Ramos","year":"2022","journal-title":"World J Urol."},{"key":"10.1016\/j.acuroe.2024.04.005_bib0130","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1007\/s00345-023-04332-z","article-title":"Efficacy of hyperthermic intravesical chemotherapy (HIVEC) in patients with non-muscle invasive bladder cancer after BCG failure","volume":"41","author":"Pignot","year":"2023","journal-title":"World J Urol."},{"key":"10.1016\/j.acuroe.2024.04.005_bib0135","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.eururo.2018.09.005","volume":"75","author":"Tan","year":"2019","journal-title":"Eur Urol."},{"key":"10.1016\/j.acuroe.2024.04.005_bib0140","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1186\/s12885-018-5134-7","article-title":"ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk \"BCG failure\" non muscle invasive bladder cancer: 3 years follow-up outcomes","volume":"18","author":"Racioppi","year":"2018","journal-title":"BMC Cancer."},{"key":"10.1016\/j.acuroe.2024.04.005_bib0145","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Powles","year":"2022","journal-title":"Ann Oncol."},{"key":"10.1016\/j.acuroe.2024.04.005_bib0150","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1158\/1078-0432.CCR-19-1920","article-title":"Adaptive immune resistance to intravesical BCG in non-muscle invasive bladder cancer: implications for prospective BCG-unresponsive trials","volume":"26","author":"Kates","year":"2020","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.acuroe.2024.04.005_bib0155","doi-asserted-by":"crossref","first-page":"34066","DOI":"10.18632\/oncotarget.26122","article-title":"Enhanced expression of PD-L1 in non-muscle-invasive bladder cancer after treatment with Bacillus Calmette-Guerin","volume":"9","author":"Hashizume","year":"2018","journal-title":"Oncotarget."},{"key":"10.1016\/j.acuroe.2024.04.005_bib0160","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol."},{"issue":"Suppl 6","key":"10.1016\/j.acuroe.2024.04.005_bib0165","first-page":"41","article-title":"Pembrolizumab monotherapy for patients with high-risk non-muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guerin: results from cohort B of the phase 2 Keynote-057 trial","volume":"41","author":"Necchi","year":"2023","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.acuroe.2024.04.005_bib0170","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.eururo.2023.08.004","article-title":"Phase 2 trial of atezolizumab in Bacillus Calmette-Guerin-unresponsive high-risk non-muscle-invasive bladder cancer: SWOG S1605","volume":"84","author":"Black","year":"2023","journal-title":"Eur Urol."},{"key":"10.1016\/j.acuroe.2024.04.005_bib0175","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.urolonc.2021.01.025","article-title":"Fibroblast growth factor receptor: a systematic review and meta-analysis of prognostic value and therapeutic options in patients with urothelial bladder carcinoma","volume":"39","author":"Kardoust Parizi","year":"2021","journal-title":"Urol Oncol."},{"issue":"Suppl 6","key":"10.1016\/j.acuroe.2024.04.005_bib0180","article-title":"Phase 2 study of the efficacy and safety of erdafitinib in patients with bacillus Calmette-Guerin unresponsive high-risk non-muscle-invasive bladder cancer with FGFR3\/2 alterations in THOR-2: cohort 2 interim results","volume":"41","author":"Catto","year":"2023","journal-title":"J Clin Oncol."},{"issue":"Suppl 6","key":"10.1016\/j.acuroe.2024.04.005_bib0185","article-title":"Phase 2 study of the efficacy and safety of erdafitinib in patients with intermediate-risk non muscle invasive bladder cancer with FGFR3\/2 alterations in THOR-2: cohort 3 interim analysis","volume":"41","author":"Daneshmand","year":"2023","journal-title":"J Clin Oncol."},{"issue":"Suppl 16","key":"10.1016\/j.acuroe.2024.04.005_bib0190","article-title":"A phase 3 study of the subcutaneous programmed cell death protein 1 inhibitor sasanlimab as sasanlimab as single agent for patients with BCG unresponsive high risk non-muscle invasive bladder cancer. CREST study cohort B","volume":"40","author":"Shore","year":"2022","journal-title":"J Clin Oncol."},{"issue":"Suppl 7","key":"10.1016\/j.acuroe.2024.04.005_bib0195","first-page":"37","article-title":"A phase III, randomized, open-label, multicenter, global study of durvalumab and Bacillus Calmette-Gu\u00e9rin (BCG) versus BCG alone in high-risk, BCG-na\u00efve non-muscle-invasive bladder cancer (NMIBC) patients (POTOMAC). ASCO Genitourinary Cancers Symposium2019","volume":"37","author":"Santis","year":"2019","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.acuroe.2024.04.005_bib0200","series-title":"Presented at: 2021 AUA Annual Meeting","article-title":"Interim analysis of a phase I single-arm study of the combination of durvalumab (MEDI4736) and Vicineum (oportuzumab monatox, VB4-845) in subjects with high-grade non-muscle-invasive bladder cancer previously treated with Bacillus Calmette-Guerin","author":"Gurram","year":"2021"},{"issue":"Suppl 15","key":"10.1016\/j.acuroe.2024.04.005_bib0205","first-page":"38","article-title":"A phase II, randomized study of nivolumab (NIVO), NIVO plus linrodostat mesylate, or NIVO plus intravesical bacillus Calmette-Guerin (BCG) in BCG-unresponsive, highrisk, nonmuscle invasive bladder cancer (NMIBC): CheckMate 9UT","volume":"38","author":"Hahn","year":"2020","journal-title":"J Clin Oncol."},{"issue":"Suppl 16","key":"10.1016\/j.acuroe.2024.04.005_bib0210","first-page":"40","article-title":"Phase 1a\/b safety study of intravesical instillation of TARA002 in adults with high-grade non-muscle invasive bladder cancer (ADVANCED-1)","volume":"40","author":"Bandari","year":"2022","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.acuroe.2024.04.005_bib0215","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.eururo.2012.08.009","article-title":"ICUD-EAU International Consultation on Bladder Cancer 2012: radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder","volume":"63","author":"Gakis","year":"2013","journal-title":"Eur Urol."},{"key":"10.1016\/j.acuroe.2024.04.005_bib0220","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nrurol.2017.16","article-title":"BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG","volume":"14","author":"Kamat","year":"2017","journal-title":"Nat Rev Urol."},{"key":"10.1016\/j.acuroe.2024.04.005_bib0225","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00345-006-0112-0","article-title":"Treatment options for BCG failures","volume":"24","author":"O\u2019Donnell","year":"2006","journal-title":"World J Urol."},{"key":"10.1016\/j.acuroe.2024.04.005_bib0230","article-title":"Phase 2b study of TAR-200 plus cetrelimab, TAR-200 alone, or cetrelimab alone in participants with highrisk nonmuscle-invasive bladder cancer unresponsive to Bacillus Calmette-Gu\u00e9rin who are ineligible for or decline radical cystectomy","volume":"40","author":"Heijden","year":"2022","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.acuroe.2024.04.005_bib0235","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.4508","article-title":"Final clinical results of pivotal trial of IL-15R\u03b1Fc superagonist N-803 with BCG in BCG-unresponsive CIS and papillary nonmuscle-invasive bladder cancer (NMIBC)","volume":"40","author":"Chamie","year":"2022","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.acuroe.2024.04.005_bib0240","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0022-5347(05)65757-6","article-title":"Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed","volume":"166","author":"O\u2019Donnell","year":"2001","journal-title":"J Urol."},{"key":"10.1016\/j.acuroe.2024.04.005_bib0245","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.urolonc.2005.11.026","article-title":"Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer","volume":"24","author":"Joudi","year":"2006","journal-title":"Urol Oncol."},{"key":"10.1016\/j.acuroe.2024.04.005_bib0250","article-title":"Intravesical Bacillus Calmette-Guerin with interferon-alpha versus intravesical Bacillus Calmette-Guerin for treating non-muscle-invasive bladder cancer","volume":"3","author":"Shepherd","year":"2017","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.acuroe.2024.04.005_bib0255","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.juro.2008.11.019","article-title":"Intravesical mycobacterial cell wall-DNA complex in the treatment of carcinoma in situ of the bladder after standard intravesical therapy has failed","volume":"181","author":"Morales","year":"2009","journal-title":"J Urol."},{"key":"10.1016\/j.acuroe.2024.04.005_bib0260","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.juro.2014.09.109","article-title":"Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with bacillus Calmette-Guerin","volume":"193","author":"Morales","year":"2015","journal-title":"J Urol."},{"key":"10.1016\/j.acuroe.2024.04.005_bib0265","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/BLC-160084","article-title":"Efficacy of Mycobacterium Phlei Cell Wall-Nucleic Acid Complex (MCNA) in BCG-unresponsive patients","volume":"3","author":"Li","year":"2017","journal-title":"Bladder Cancer."},{"issue":"Suppl 16","key":"10.1016\/j.acuroe.2024.04.005_bib0270","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1200\/JCO.2022.40.16_suppl.4597","article-title":"Kamat Trinity Bivalacqua. CORE1: phase 2, singlearm study of CG0070 combined with pembrolizumab in patients with nonmuscle-invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG)","volume":"40","author":"Li","year":"2022","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.acuroe.2024.04.005_bib0275","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.eururo.2023.01.017","article-title":"A phase 1 trial of durvalumab in combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in patients with BCG-unresponsive non-muscle-invasive bladder cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER study","volume":"83","author":"Hahn","year":"2023","journal-title":"Eur Urol."}],"container-title":["Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173578624000325?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173578624000325?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T05:31:41Z","timestamp":1717738301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173578624000325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S2173578624000325"],"URL":"https:\/\/doi.org\/10.1016\/j.acuroe.2024.04.005","relation":{},"ISSN":["2173-5786"],"issn-type":[{"value":"2173-5786","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multidisciplinary consensus document on the current treatment of bacille Calmette-Gu\u00e9rin-unresponsive non-muscle invasive bladder tumor","name":"articletitle","label":"Article Title"},{"value":"Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acuroe.2024.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.acuro.2024.01.008","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 AEU. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}